Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ( Oncotelic ), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business activities through Oncotelic and its wholly-owned subsidiaries, On…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
$248M
▲ +5610.2% YoY
Op. Margin
–
ROIC
-2.25%
▲ +19.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$2M
▼ -86.8% YoY
Op. Cash Flow (TTM)
-$2M
▼ -86.8% YoY
Net Debt
$2M
Cash & Equiv.
$186K
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with OTLC
Oncotelic Therapeutics (OTLC) in three numbers
Questions about Oncotelic Therapeutics
Is Oncotelic Therapeutics (OTLC) overvalued?
Oncotelic Therapeutics trades at 0.03 times earnings. Intrinsiqq's fair value calculator has no opening value for OTLC, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Oncotelic Therapeutics a high-quality business?
Oncotelic Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 7 checks computed from SEC filings. Its best check is revenue growth at -23.4%. The Quality tab shows every check against its target.
Does Oncotelic Therapeutics (OTLC) pay a dividend?
No. Oncotelic Therapeutics (OTLC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 13 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in OTLC's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing OTLC
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.